At1 antagonism and renin inhibition in mice: Pivotal role of targeting angiotensin II in chronic kidney disease

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 7, 2012, Pages

  Fraune, Christoph ^a   Lange, Sascha ^a   Krebs, Christian ^a   Hölzel, Alexandra ^a   Baucke, Jana ^a   Divac, Nevena ^b   Schwedhelm, Edzard ^a   Streichert, Thomas ^a   Velden, Joachim ^a   Garrelds, Ingrid M ^c   Jan Danser, A H ^c   Frenay, Anne Roos ^d   van Goor, Harry ^d   Jankowski, Vera ^e   Stahl, Rolf ^a   Nguyen, Genevieve ^f   Wenzel, Ulrich Otto ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f l'alimentation et l'Environnement   (France)

Author keywords

5 6 nephrectomy; Renal impairment

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; BIOLOGICAL MARKER; LOSARTAN; RENIN; AMIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; FUMARIC ACID DERIVATIVE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GLOMERULUS; KIDNEY INJURY; KIDNEY PARENCHYMA; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR BLOCKING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; ANIMAL; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; DRUG EFFECT; KIDNEY; METABOLISM;

ALBUMINURIA; AMIDES; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FUMARATES; GENE EXPRESSION; KIDNEY; LOSARTAN; MALE; MICE; RENAL INSUFFICIENCY, CHRONIC; RENIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 84867112167     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00672.2011     Document Type: Article

References (41)

1. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77: 1993-2000, 1986.
2. Batenburg WW, de Bruin RJ, van Gool JM, Muller DN, Bader M, Nguyen G, Danser AH. Aliskiren-binding increases the half life of rennin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 28: 1151-1157, 2008.
3. Benndorf RA, Krebs C, Hirsch-Hoffmann B, Schwedhelm E, Cieslar G, Schmidt-Haupt R, Steinmetz OM, Meyer-Schwesinger C, Thaiss F, Haddad M, Fehr S, Heilmann A, Helmchen U, Hein L, Ehmke H, Stahl RA, Boger RH, Wenzel UO. Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice. Kidney Int 75: 1039-1049, 2009.
4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
5. Burnier M, Brede Y, Lowy A. Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril. Int J Clin Pract 65: 127-133, 2011.
6. Campbell DJ, Nussberger J, Stowasser M, Danser AH, Morganti A, Frandsen E, Menard J. Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 55: 867-877, 2009.
7. de Lannoy LM, Danser AH, van Kats JP, Schoemaker RG, Saxena PR, Schalekamp MA. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. Hypertension 29: 1240-1251, 1997.
8. Dong YF, Liu L, Lai ZF, Yamamoto E, Kataoka K, Nakamura T, Fukuda M, Tokutomi Y, Nako H, Ogawa H, Kim-Mitsuyama S. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens 28: 1554-1565, 2010.
9. Feldman DL. New insights into the renoprotective actions of the rennin inhibitor aliskiren in experimental renal disease. Hypertens Res 33: 279-287, 2010.
10. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52: 130-136, 2008.
11. Ganten D, Wagner J, Zeh K, Bader M, Michel JB, Paul M, Zimmermann F, Ruf P, Hilgenfeldt U, Ganten U. Species specificity of rennin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci USA 89: 7806-7810, 1992.
12. Gross O, Girgert R, Rubel D, Temme J, Theissen S, Muller GA. Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis. Am J Hypertens 24: 355-361, 2011.
13. Hamming I, Goor H, Navis GJ. ACE inhibitor use and the increased long-term risk of renal failure in diabetes. Kidney Int 70: 1377-1378, 2006.
14. Hamming I, Navis G, Kocks MJ, van Goor H. ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J Pathol 209: 129-139, 2006.
15. Ichihara A, Sakoda M, Kurauchi-Mito A, Narita T, Kinouchi K, Bokuda K, Itoh H. New approaches to blockade of the renin-angiotensinaldosterone system: characteristics and usefulness of the direct rennin inhibitor aliskiren. J Pharmacol Sci 113: 296-300, 2010.
16. Iwai M, Kanno H, Tomono Y, Inaba S, Senba I, Furuno M, Mogi M, Horiuchi M. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. J Hypertens 28: 1471-1481, 2010.
17. Jankowski V, Tolle M, Santos RA, Gunthner T, Krause E, Beyermann M, Welker P, Bader M, Pinheiro SV, Sampaio WO, Lautner R, Kretschmer A, van der Giet M, Zidek W, Jankowski J. Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects. FASEB J 25: 2987-2995, 2011.
18. Jankowski V, Vanholder R, van der Giet M, Henning L, Tolle M, Schonfelder G, Krakow A, Karadogan S, Gustavsson N, Gobom J, Webb J, Lehrach H, Giebing G, Schluter H, Hilgers KF, Zidek W, Jankowski J. Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension 46: 591-597, 2005.
19. Jankowski V, Vanholder R, van der Giet M, Tolle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN, Tepel M, Schuchardt M, Schluter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, Jankowski J. Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 27: 297-302, 2007.
20. Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 7: 399-410, 2008.
21. Kang YS, Lee MH, Song HK, Hyun YY, Cha JJ, Ko GJ, Kim SH, Lee JE, Han JY, Cha DR. Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol Dial Transplant 26: 1194-1204, 2011.
22. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 50: 2398-2404, 2007.
23. Kirchhoff F, Krebs C, Abdulhag UN, Meyer-Schwesinger C, Maas R, Helmchen U, Hilgers KF, Wolf G, Stahl RA, Wenzel U. Rapid development of severe end-organ damage in C57BL/6 mice by combining DOCA salt and angiotensin II. Kidney Int 73: 643-650, 2008.
24. Krebs C, Hamming I, Sadaghiani S, Steinmetz OM, Meyer-Schwesinger C, Fehr S, Stahl RA, Garrelds IM, Danser AH, van Goor H, Contrepas A, Nguyen G, Wenzel U. Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int 72: 725-730, 2007.
25. Krebs C, Weber M, Steinmetz O, Meyer-Schwesinger C, Stahl R, Danser AH, Garrelds I, van Goor H, Nguyen G, Muller D, Wenzel U. Effect of (pro)renin receptor inhibition by a decoy peptide on renal damage in the clipped kidney of Goldblatt rats. Kidney Int 74: 823-824, 2008.
26. Krop M, Garrelds IM, de Bruin RJ, van Gool JM, Fisher ND, Hollenberg NK, Jan Danser AH. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension 52: 1076-1083, 2008.
27. Lu H, Rateri DL, Feldman RJ DL Jr, Fukamizu A, Ishida J, Oesterling EG, Cassis LA, Daugherty A. Renin inhibition reduces hypercholesterolemiainduced atherosclerosis in mice. J Clin Invest 118: 984-993, 2008.
28. Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 35: 985-991, 2000.
29. Meyer TW, Anderson S, Rennke HG, Brenner BM. Converting enzyme inhibitor therapy limits progressive glomerular injury in rats with renal insufficiency. Am J Med 79: 31-36, 1985.
30. Nussberger J, Aubert J, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 51: 1306-1311, 2008.
31. Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 24: 93-103, 2010.
32. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433-2446, 2008.
33. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Muller DN. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46: 569-576, 2005.
34. Poss J, Werner C, Lorenz D, Gensch C, Bohm M, Laufs U. The rennin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice. Basic Res Cardiol 105: 725-735, 2010.
35. Rakusan D, Kujal P, Kramer HJ, Huskova Z, Vanourkova Z, Vernerova Z, Mrazova I, Thumova M, Cervenka L, Vaneckova I. Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. Am J Physiol Renal Physiol 299: F758-F766, 2010.
36. van Esch JH, Moltzer E, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, Danser AH. Beneficial cardiac effects of the rennin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens 28: 2145-2155, 2010.
37. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlen A, Pettersson A, Nyberg F, Fandriks L, Gallo-Payet N, Hallberg A, Alterman M. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 47: 5995-6008, 2004.
38. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, Ruger H, Goschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, Schnell CR, Herold P, Mah R, Jensen C, O'Brien E, Stanton A, Bedigian MP. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308: 698-705, 2003.
39. Wu WP, Chang CH, Chiu YT, Ku CL, Wen MC, Shu KH, Wu MJ. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. Am J Physiol Renal Physiol 299: F929-F941, 2010.
40. Yamamoto E, Kataoka K, Dong YF, Nakamura T, Fukuda M, Tokutomi Y, Matsuba S, Nako H, Nakagata N, Kaneko T, Ogawa H, Kim-Mitsuyama S. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthasedeficient mice. Hypertension 54: 633-638, 2009.
41. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559, 2008.